Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ji-Won Kim"'
Autor:
Ju Hyun Lee, Jin Won Kim, Koung Jin Suh, Yu Jung Kim, Ki Hwan Kim, Jin Soo Kim, Jee Hyun Kim, Jin Hyun Park, In Sil Choi, Ji Won Kim
Publikováno v:
European journal of cancer (Oxford, England : 1990). 154
Background In locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin. This study evaluated whether irinotecan/5-fluorouracil (5-FU; mFOLFIRI) was supe
Autor:
Tri Ho Minh, Mi Eun Choi, Jeong Mi Kim, Young-Mo Kim, Ji Won Kim, Eun Jeong Jeon, Jeong-Seok Choi, Jin-Mi Park
Publikováno v:
Oral oncology. 120
Background We examined the regenerative efficacy of the activated platelet-rich plasma (PRP) concentrate administered by local injection in an animal model mimicking partial glossectomy for tongue cancer. Methods Four-week-old mice were randomized to
Autor:
Sang Hoon Ahn, Hye Seung Lee, Do Joong Park, Hyung Ho Kim, Ji Won Kim, Jin Won Kim, Kui Jin Kim, Keun Wook Lee, Jieun Kim, Jiwon Koh, Ji Hea Sung, Koung Jin Suh
Publikováno v:
PLoS ONE, Vol 16, Iss 6, p e0252480 (2021)
PLoS ONE
PLoS ONE
Peripheral regulatory T cells (pTregs) are a highly immunosuppressive fraction of CD4+ T cells. We aimed to evaluate the clinical significance of pTregs in patients with gastric cancer and to determine the correlation between pTregs and immune cell i
Autor:
Chao-Hui Zheng, Soo-Jeong Cho, Sandra Ryeom, Yu Xu, Changhwan Yoon, Sam S. Yoon, Duane T. Smoot, Chang-Ming Huang, Long-Long Cao, Jun Lu, Hassan Ashktorab, Xiao-yan Huang, Ji Won Kim, Ping Li
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy.
Chemoresistance is the major cause of gastric adenocarcinoma (GA) treatment failure. The mechanisms underlying chemoresistance remain incompletely understood. Here, we sought to identify genes differentially expressed between chemoresistant and chemo
Autor:
Jeong Ok Lee, Seonyang Park, Inho Kim, Young Il Koh, Soo Mee Bang, Hyunkyung Park, Sung-Soo Yoon, Kihwan Kim, Ji Won Kim, Jeonghwan Youk
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:408-414
Background AL amyloidosis might increase the risk of thromboembolism and other plasma cell dyscrasias; however, only a few reports have described the clinical features of thromboembolism. The present study aimed to elucidate the clinical features of
Autor:
Haeryoung Kim, Jaihwan Kim, Yu Jung Kim, Yoo Seok Yoon, YoungRok Choi, Jin Won Kim, Keun Wook Lee, Jin-Hyeok Hwang, Ho-Seong Han, Ji Won Kim, Sehhoon Park, Jee Hyun Kim, Jai Young Cho
Publikováno v:
APMIS. 125:699-707
Resectable pancreatic cancer has a high recurrence rate after curative surgery. Biomarkers are needed for distinguishing patients who may benefit from curative resection. In this study, we sought to analyze the prognostic value of p21-activated kinas
Autor:
Kui-Jin Kim, Hun Jee Choe, Koung Jin Suh, Hye Seung Lee, Keun-Wook Lee, Ji Won Kim, Jin Won Kim, Song-Hee Han, Jeong-Min Kim
Publikováno v:
Cancer Research. 79:3750-3750
Background: While additional gastrectomy has not shown superiority compared to conventional systemic therapy in unresectable gastric cancer in REGATTA trial, there have been several subsequent attempts to find a role for conversion surgery with a cur
Publikováno v:
Oncology Reports. 30:485-491
Arsenic trioxide (As(2)O(3)) has shown substantial efficacy in the treatment of patients with acute promyelocytic leukemia, a specific subtype of acute myeloid leukemia (AML). However, since not all patients can achieve remission after treatment, it
Publikováno v:
Journal of Clinical Oncology. 36:66-66
66 Background: Peripheral regulatory T cells (pTregs) might involve in tumor immune microenvironment. We aim to evaluate the correlation between pTregs and tumor immune microenvironment. Methods: pTregs status was determined from assessment of the pT
Autor:
Sanghoon Jheon, Sung Bum Kang, Koung Jin Suh, Sukki Cho, Duck-Woo Kim, Sang-A Kim, Heung Kwon Oh, Keun-Wook Lee, Jin Won Kim, Ji Won Kim, Jai Young Cho, Jee Hyun Kim, Kwhanmien Kim
Publikováno v:
Journal of Clinical Oncology. 36:843-843
843 Background: Some mCRC pts who have liver and/or lung metastases (LLMs) could achieve cure after palliative chemotherapy and conversion surgery (CS) including metastasectomy. Though targeted agents including bevacizumab and cetuximab significantly